TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

Nature Medicine

Volumn 9, Issue 9, 2003, Pages 1202-1208

  Belghith, Mériam ^a   Bluestone, Jeffrey A ^b   Barriot, Samia ^a   Mégret, Jérôme ^a   Bach, Jean François ^a   Chatenoud, Lucienne ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY CD3; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG MECHANISM; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REMISSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; IMMUNE TOLERANCE; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, INTERLEUKIN-2; SPLEEN; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 0141796312     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm924     Document Type: Article

References (46)

1. Simone, E.A., Wegmann, D.R. & Eisenbarth, G.S. Immunologic "vaccination" for the prevention of autoimmune diabetes (type 1A). Diabetes Care 22 (suppl. 2), B7-B15 (1999).
2. Bach, J.F. & Chatenoud, L. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19, 131-161 (2001).
3. Chatenoud, L., Thervet, E., Primo, J. & Bach, J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in non obese diabetic mice. Proc. Natl. Acad. Sci. USA 91, 123-127 (1997).
4. Chatenoud, L., Primo, J. & Bach, J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158, 2947-2954 (1997).
5. Ferran, C. et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20, 509-515 (1990).
6. Hirsch, R., Gress, R.E., Pluznik, D.H., Eckhaus, M. & Bluestone, J.A. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 142, 737-743 (1989).
7. Chatenoud, L., Legendre, C., Ferran, C., Bach, J.F. & Kreis, H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites. Transplantation 51, 334-338 (1991).
8. Abramowicz, D. et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47, 606-608 (1989).
9. Hirsch, R., Bluestone, J.A., de Nenno, L. & Gress, R.E. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49, 1117-1123 (1990).
10. Woodle, E.S. et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68, 608-616 (1999).
11. Friend, P.J. et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68, 1632-1637 (1999).
12. Herold, K.C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346,1692-1698 (2002).
13. Chatenoud, L. et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur. J. Immunol. 12, 979-982 (1982).
14. Hirsch, R., Eckhaus, M., Auchincloss, H.J.R., Sachs, D.H. & Bluestone, J.A. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J. Immunol. 140, 3766-3772 (1988).
15. Chatenoud, L. & Bach, J.F. Antigenic modulation: a major mechanism of antibody action. Immunol. Today 5, 20-25 (1984).
16. + splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 169, 2461-2465 (2002).
17. Asano, M., Toda, M., Sakaguchi, N. & Sakaguchi, S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184, 387-396 (1996).
18. Takahashi, T. et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
19. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162, 5317-5327(1999).
20. Suri-Payer, E., Kehn, P.J., Cheever, A.W. & Shevach, E.M. Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/ K adenosine triphosphatase-reactive T cells. J. Immunol. 157, 1799-1808 (1996).
21. Stephens, L.A. & Mason, D. CD25 is a marker for CD4(+) thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25(+) and CD25(-) subpopulations. J. Immunol. 165, 3105-3110 (2000).
22. Boitard, C., Yasunami, R., Dardenne, M. & Bach, J.F. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J. Exp. Med. 169, 1669-1680 (1989).
23. Lepault, F., Gagnerault, M.C., Faveeuw, C., Bazin, H. & Boitard, C. Lack of L-selectin expression by cells transferring diabetes in NOD mice: insights into the mechanisms involved in diabetes prevention by Mel-14 antibody treatment. Eur. J. Immunol. 25, 1502-1507 (1995).
24. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
25. Chatenoud, L., Salomon, B. & Bluestone, J.A. Suppressor T cells - they're back and critical for the regulation of autoimmunity. Immunol. Rev. 182, 149-163 (2001).
26. Lenschow, D.J. et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5, 285-293 (1996).
27. Nakamura, K., Kitani, A. & Strober, W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194, 629-639 (2001).
28. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10, 1969-1979 (1998).
29. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296 (1998).
30. Piccirillo, C.A. et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J. Exp. Med. 196, 237-246 (2002).
31. Wang, B. et al. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 47, 1207-1211 (1998).
32. Lucas, C. et al. The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J. Immunol. 145,1415-1425 (1990).
33. Bridoux, F. et al. Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines. J. Exp. Med. 185, 1769-1779 (1997).
34. Mallat, Z. et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89, 930-940 (2001).
35. Seddon, B. & Mason, D. Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC(-) cells and CD4(+)CD8(-) thymocytes. J. Exp. Med. 189, 279-289 (1999).
36. Read, S., Malmstrom, V. & Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
37. + T cells. J. Exp. Med. 188, 1849-1857 (1998).
38. Yasunami, R. & Bach, J.F. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur. J. Immunol. 18, 481-491 (1988).
39. + T cells. J. Exp. Med. 183, 2669-2679 (1996).
40. + T suppressor clones profuse transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196, 1335-1346 (2002).
41. Ludviksson, B.R., Ehrhardt, R.O. & Strober, W. TGF-β production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J. Immunol. 159, 3622-3628 (1997).
42. Papiernik, M., de Moraes, M.L., Pontoux, C., Vasseur, F. & Penit, C. Regulatory CD4 T cells: expression of IL-2R α chain, resistance to clonal deletion and IL-2 dependency. Int. Immunol. 10, 371-378 (1997).
43. - regulatory cells mediate dominant transplantation tolerance. J. Immunol. 168, 5558-5565 (2002).
44. Luhder, F., Hoglund, P., Allison, J.P., Benoist, C. & Mathis, D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187, 427-432 (1998).
45. Alegre, M.L. et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155, 1544-1555 (1995).
46. Walunas, T.L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413 (1994).